Phase II trial of S-1 and lentinan combined chemotherapy for elderly patients with unresectable advanced gastric cancer

Phase II trial of S-1 and lentinan combined chemotherapy for elderly patients with unresectable advanced gastric cancer - Phase II trial of S-1 and lentinan

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000026975

Enrollment

Registered

2017-04-13

Start date

2008-10-30

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Unresectable advanced gastric cancer

Interventions

TS-1/lentinan

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Histologically proven gastric cancer 2. Aged over 70 years at the time of registration 3.Unresectable advanced gastric cancer 4.Performance status (ECOG): 0-2 5.Previously not treated chemotherapy or radiotherapy for unresectable gastric cancer 6.Sufficient organ functions 7.Life expectance estimated>=3 months 8.Able to receive oral S-1 treatment 9.Written informed consent

Exclusion criteria

Exclusion criteria: 1.Administration contraindication of S-1 2.Active infectious 3.Serious heart disease or the past history 4.Serious coexisting illness 5.Massive abdominal or pleural effusion 6.Multiple bone metastases 7.Brain metastasis or the past history 8.Active gastrointestinal bleeding 9. Mental disorder to need a psychotropic drug 10. Hypersensitivity to lentinan 11.Inappropriate patients for this study judged by the physicians

Design outcomes

Primary

Measure	Time frame
Overall survival	—

Countries

Japan

Contacts

Public ContactSatomi Oyama

Saitama Medical Center, Saitama Medical University Department of digestive tract and general surgery

osato@saitama-med.ac.jp048-228-3619

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026